Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation

Abstract

A composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias is described. The composition, for human and animal use as an antitumor agent, has a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (Th1) interferon INF-gamma, the cytokines exhibiting a marked antitumor activity, and/or a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which is able to strongly stimulate the production of dendritic cells, the dendritic cells also exhibiting a marked antitumor activity.

1 . A composition comprising a mixture consisting of:
 a strain of bacteria belonging to the species  Lactobacillus reuteri  identified as  Lactobacillus reuteri  LRE03 with deposit number DSM 23879, deposited on 5 Aug. 2010 by Probiotical SpA at DSMZ—Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, and/or   a strain of bacteria belonging to the species  Lactobacillus salivarius  identified as  Lactobacillus salivarius  LS06 with deposit number DSM 26037, deposited on 6 Jun. 2012 by Probiotical SpA at DSMZ—Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH,   in an amount effective for antitumor chemotherapeutic treatment, acquired immunodeficiency syndrome treatment and leukemia treatment.   
     
     
         2 . The composition according to  claim 1 , wherein said mixture has a bacterial concentration comprised from 1×10 8  UFC/g of mixture to 1×10 12  UFC/g of mixture. 
     
     
         3 . The composition according to  claim 1 , wherein said mixture comprises:
 a strain of bacteria  Lactobacillus reuteri  LRE03 DSM 23879 and a strain of bacteria  Lactobacillus salivarius  LS06 DSM 26037, in a weight ratio comprised from 1:5 to 5:1.   
     
     
         4 . The composition according to  claim 1 , wherein said composition further comprises an  Aloe  gel or a derivative thereof. 
     
     
         5 . The composition according to  claim 1 , wherein said composition further comprises a freeze-dried  Aloe arborescens  in an amount comprised from 1 to 25% by weight, relative to the weight of the composition. 
     
     
         6 . The composition according to  claim 1 , wherein said composition further comprises a tyndallized bacterial product of  Bifidobacterium lactis  Bb 1 with deposit number DSM 17850, deposited at DSMZ on 23 Dec. 2005, by BioMan S.r.l. Company. 
     
     
         7 . The composition according to  claim 6 , wherein said tyndallized bacterial product of the strain  Bifidobacterium animalis  ssp.  lactis  Bb1 DSM 17850 is in an amount comprised from 10 to 50 mg/g of the composition. 
     
     
         8 . The composition according to  claim 1 , wherein said composition further comprises one or more food grade excipients or pharma grade excipients, and/or additives acceptable by the body, and/or co-formulants acceptable by the body. 
     
     
         9 . The composition according to  claim 1 , wherein said strain of bacteria belonging to the species  Lactobacillus reuteri  and strain of bacteria belonging to the species  Lactobacillus salivarius  are in an amount effective to treat tumors in human and animal. 
     
     
         10 . The composition according to  claim 1 , wherein said composition has a bacterial concentration from 1×10 9  UFC/g to 1×10 11  UFC/g. 
     
     
         11 . The composition according to  claim 1 , wherein said composition comprises a strain of bacteria  Lactobacillus reuteri  LRE03 DSM 23879 and a strain of bacteria  Lactobacillus salivarius  LS06 DSM 26037, in a weight ratio from 1:3 to 3:1. 
     
     
         12 . The composition according to  claim 1 , wherein said composition comprises a strain of bacteria  Lactobacillus reuteri  LRE03 DSM 23879 and a strain of bacteria  Lactobacillus salivarius  LS06 DSM 26037, in a weight ratio from 1:2 to 2:1 
     
     
         13 . The composition according to  claim 1 , wherein said composition comprises a strain of bacteria  Lactobacillus reuteri  LRE03 DSM 23879 and a strain of bacteria  Lactobacillus salivarius  LS06 DSM 26037, in a weight ratio of 1:1. 
     
     
         14 . The composition according to  claim 1 , wherein said composition further comprises an  Aloe arborescens  gel. 
     
     
         15 . The composition according to  claim 14 , wherein the  Aloe arborescens  gel is freeze-dried. 
     
     
         16 . The composition according to  claim 1 , wherein said composition further comprises a freeze-dried  Aloe arborescens  in an amount from 5 to 15% by weight, relative to the weight of the composition. 
     
     
         17 . The composition according to  claim 6 , wherein said tyndallized bacterial product of the strain  Bifidobacterium animalis  ssp.  lactis  Bb1 DSM 17850 is in an amount of 20 mg/g of composition. 
     
     
         18 . The composition according to  claim 1 , wherein said composition further comprises fructooligosaccharides (FOS), green tea, sucralose, and/or maltodextrins. 
     
     
         19 . The composition according to  claim 1 , wherein the composition further comprises highly bioavailable zinc. 
     
     
         20 . The composition according to  claim 19 , wherein the highly bioavailable zinc is internalized inside a tyndallized bacterial cell of the strain  Bifidobacterium animalis  ssp.  lactis  Bb1 DSM 17850.